Health Condition 1: -
Conditions
Interventions
None listed
Sponsors
Biocon Limited
Eligibility
Inclusion criteria
Inclusion criteria: Patient aged � 18 years Patients who are willing to provide written and signed informed consent for collecting health data into the registry Patients with EBC who are eligible to receive treatment with Trastuzumab as per the approved prescribing information and clinical judgment of the treating oncologist
Exclusion criteria
Exclusion criteria: 1. Have a history of hypersensitivity to Trastuzumab or other components of the product 2. Patient with any contraindication as mentioned in approved prescribing information of Trastuzumab biosimilar 3. Any other reason (concurrent disease or condition) in the opinion of the oncologist that would make the patient unsuitable for participation in the registry
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study safety of similar biologics Trastuzumab in the treatment of patients diagnosed with HER2+ early breast cancer (EBC)Timepoint: All the adverse event data will be collected throughout study duration as assessed in routine practice by treating oncologist, maximum up to 2 years | — |
Countries
India
Contacts
Public ContactJayanti Panda
Biocon Research Limited "Biocon"
Outcome results
None listed